Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07132801 · ClinicalTrials.gov registry record · NA
Comparison of Two Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels
A NA study, sponsored by Qualia Life Sciences.
- Not yet
- Registry status
- NA
- Development phase
- 180
- Enrollment target
NCT07132801 is a NA study that has not yet begun recruiting, run by Qualia Life Sciences. The registered enrollment target is 180 participants.
The verdict
NCT07132801, a NA study, has not yet begun recruiting, sponsored by Qualia Life Sciences.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 180 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, parallel-group study evaluating the effects of two distinct Qualia NAD⁺ formulations on intracellular NAD⁺ levels in healthy adults aged 35-75 years. Approximately 180 participants will be randomized to one of three study arms: Qualia NAD⁺ version 1, Qualia NAD⁺ version 2, or placebo. Each participant will take two capsules of their assigned product once daily in the morning, with or without food, over a 28-day period. The primary outcome is the change in intracellular NAD⁺ levels, assessed via at-home finger-stick blood collection at baseline and study completion. Secondary endpoints include changes in aging-related symptoms (AMFS scores), health-related quality of life (RAND SF-36), and evaluation of safety and tolerability. All assessments, including electronic questionnaires, are completed remotely without in-person visits.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Qualia NAD⁺ version 1
- DIETARY_SUPPLEMENT Qualia NAD⁺ version 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2025-10-13 |
| Est. Completion | 2025-12-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07132801
The ClinicalTrials.gov registry entry for NCT07132801 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Qualia Life Sciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07132801 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07132801 about?
NCT07132801 is a clinical study titled "Comparison of Two Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels". This is a randomized, double-blind, placebo-controlled, parallel-group study evaluating the effects of two distinct Qualia NAD⁺ formulations on intracellular NAD⁺ levels in healthy adults aged 35-75 years. Approximately 180 participants will be randomized to one of three study arms: Qualia NAD⁺ vers...
What is the current status of trial NCT07132801?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 180 participants. The study started on 2025-10-13. Estimated completion is 2025-12-15.
What interventions are being tested in trial NCT07132801?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Qualia NAD⁺ version 1 (DIETARY_SUPPLEMENT), Qualia NAD⁺ version 2 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07132801?
This trial is sponsored by Qualia Life Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.